HOME >> BIOLOGY >> NEWS
Joining forces

The "resistance movement" founded by bacteria to combat antibiotics may be losing ground. By combining key properties of two different types of weapons used by the innate defense systems of organisms, a team of scientists at the Weizmann Institute of Science has managed to design a more powerful weapon, hoping that this will provide a basis for novel and more effective antibiotics.

The first is a "magnetic" weapon a natural antibiotic produced by all organisms. Because these antimicrobial peptides (AMPs) are positively charged, they are attracted to the bacteria's negatively charged surface like a magnet, where they can then exert their antibacterial effects. The second, "detergent-like" weapon called a lipopeptide is produced only by bacteria and fungi which, due to a negative charge, target mainly fungi. This weapon contains a fatty acid chain that, like similar chains in soap which dissolve dirt and oils, breaks down the fatty membranes of the fungi.

As reported in the Proceedings of the National Academy of Sciences (PNAS), Prof. Yechiel Shai and Ph.D. students Arik Makovitzki and Dorit Avrahami of the Biological Chemistry Department have succeeded in combining the properties of AMPs with lipopeptides resulting in a synthetic lipopeptide that has both a positive charge and the soap-like ability to dissolve oils.

By altering the length of the fatty acid chains and the sequence of positively charged amino acids, they were able to create an array of weapons. Some are active against both bacteria and fungi, while others target just one or the other. And, as if this was not enough, they managed to design these new synthetic peptides (protein fragments) to contain only four amino acids, as opposed to the 12 50 found in their natural forms.

These findings will hopefully open up a whole range of potential applications. The short length of the synthetic peptide makes it attractive for drug design as it would be both easier
'"/>

Contact: Jennifer Manning
jennifer@acwis.org
212-895-7952
American Committee for the Weizmann Institute of Science
28-Dec-2006


Page: 1 2

Related biology news :

1. Joining hands to solve a DNA replication problem
2. Wild weather forces farmers to adapt
3. Sleep enforces the temporal sequence in memory
4. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
5. Feinstein Institute and Cold Spring Harbor Lab join forces, seek manic depression genes
6. Conservative forces hampering progress in sexual and reproductive health
7. New genetic analysis forces re-draw of insect family tree
8. Genetic research at Childrens Hospital of Pittsburgh reinforces theory of evolution
9. Texas A&M system agencies join forces to hasten bioenergy revolution
10. Salk and Stanford teams join forces to reveal two paths of neurodegeneration
11. Evolutionary forces explain why women live longer than men

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Joining forces

(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
Cached News: